Keeping Your Bladder While Treating Aggressive Bladder Cancer With Radiation and Immunotherapy

Plain-English translation of NCT07061964 on ClinicalTrials.gov ↗ · Source last updated November 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether a combination of radiation therapy and an immunotherapy drug called can help people with aggressive bladder cancer avoid having their bladder surgically removed. Participants first receive standard chemotherapy to shrink their tumors, and if the tumors respond well, they then receive the radiation and immunotherapy combination. The goal is to keep the bladder working while controlling the cancer.

Normally, aggressive bladder cancer is treated by surgically removing the entire bladder, which significantly affects quality of life. This trial explores whether this new treatment combination can be effective enough to preserve the bladder in patients whose tumors have already shrunk from initial chemotherapy.

Do you qualify?

You likely qualify if…

you have been diagnosed with aggressive (muscle-invasive) bladder cancer at stage II or IIIA
your cancer has significantly shrunk after receiving initial chemotherapy treatment (3 to 6 cycles)
imaging and biopsy show your cancer is responding well to the initial chemotherapy
you have no evidence of cancer spread to lymph nodes or distant organs after initial treatment
you are willing to receive radiation therapy five days a week for four weeks plus immunotherapy infusions over 12 months

You likely don't qualify if…

you have certain aggressive cancer variants (small cell, neuroendocrine, or plasmacytoid types)
you have had bladder cancer or related cancers outside the bladder in the past 24 months
your cancer has spread to distant organs or multiple lymph nodes despite initial chemotherapy
you have evidence of cancer remaining in the bladder after initial treatment that shows specific high-risk features

What participation looks like

If you qualify, you will receive radiation therapy once daily, Monday through Friday, for up to four weeks, combined with immunotherapy infusions every three weeks for up to one year. You will have imaging scans, cystoscopy (a camera exam of your bladder), and blood and urine tests throughout the study to monitor how well the treatment is working and check for any side effects. The study will track whether your bladder remains cancer-free and functioning over three years of follow-up.

AI-generated summary from trial data · Aug 19, 2026 · Not medical advice

Keeping Your Bladder While Treating Aggressive Bladder Cancer With Radiation and Immunotherapy

What is this trial?

Do you qualify?

What participation looks like

Trial locations(182 sites)